About
About Aikido Pharma Inc
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Visit company website
5 years, 4 months ago
AIkido Pharma Inc is currently in a long term downtrend where the price is trading 9.2% below its 200 day moving average.
From a valuation standpoint, the stock is 94.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2601.1.
AIkido Pharma Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 1367.9% to $-12M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.8% to $-3K since the same quarter in the previous year.
Based on the above factors, AIkido Pharma Inc gets an overall score of 1/5.